Sprache auswählen
APRIL
APRIL Molekülinformation
| Englischer Name | Tumor necrosis factor ligand superfamily member 13 | Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 24 | Target-Alias | Tumor Necrosis Factor Ligand 7B，CD256 Antigen，TNLG7B，CD256，TNF- and APOL-related leukocyte expressed ligand 2，TNFSF13，TNF-related death ligand 1，ZTNF2，TALL-2，APRIL，Tumor necrosis factor ligand superfamily member 13，TNF Superfamily Member 13，Tumor Necrosis Factor (Ligand) Superfamily， Member 13，TRDL-1，TALL2，Tumor Necrosis Factor Superfamily Member 13，Tumor Necrosis Factor-Like Protein ZTNF2，UNQ383/PRO715，A Proliferation-Inducing Ligand，Tumor Necrosis Factor-Related Death Ligand-1 |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Tumor necrosis factor ligand superfamily member 13 |
| Target-Alias | Tumor Necrosis Factor Ligand 7B，CD256 Antigen，TNLG7B，CD256，TNF- and APOL-related leukocyte expressed ligand 2，TNFSF13，TNF-related death ligand 1，ZTNF2，TALL-2，APRIL，Tumor necrosis factor ligand superfamily member 13，TNF Superfamily Member 13，Tumor Necrosis Factor (Ligand) Superfamily， Member 13，TRDL-1，TALL2，Tumor Necrosis Factor Superfamily Member 13，Tumor Necrosis Factor-Like Protein ZTNF2，UNQ383/PRO715，A Proliferation-Inducing Ligand，Tumor Necrosis Factor-Related Death Ligand-1 |
| Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 24 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
APRIL Produktliste
- Attribut
Protein (7)
- Produktbibliothek
Online (7)
- Spezies
Human (5)Cynomolgus (1)Mouse (1)
- Etikett
Fc Tag & Avi Tag (1)His Tag & Flag Tag (2)His Tag & Avi Tag (1)Fc Tag (3)
- Marker
Biotin-labeled (2)Unconjugated (5)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
HOT APL-H52D1 |  Human | HEK293 | Human APRIL / TNFSF13 Protein, His,Flag Tag, active trimer, low endotoxin (MALS verified) |  |  |  In den Warenkorb legen | |
HOT APL-H82Q8 | Human | HEK293 | Biotinylated Human APRIL / TNFSF13 Protein, Avitag™,His Tag, active trimer (MALS verified) | | | In den Warenkorb legen | |
HOT APL-C52D2 |  Cynomolgus | HEK293 | Cynomolgus APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified) | | | In den Warenkorb legen | |
APL-H5263 | Human | HEK293 | Human APRIL / TNFSF13 Protein, Fc Tag |  | | | In den Warenkorb legen |
APL-H5363 | Human | CHO | Human APRIL / TNFSF13 Protein, Fc Tag, low endotoxin (MALS verified) |  | | | In den Warenkorb legen |
APL-H82F5 | Human | HEK293 | Biotinylated Human APRIL / TNFSF13 Protein, Fc,Avitag™ |  | | | In den Warenkorb legen |
APL-M5363 |  Mouse | CHO | Mouse APRIL / TNFSF13 Protein, Fc Tag, low endotoxin (MALS verified) |  | | | In den Warenkorb legen |
Gesamtmenge7
- 1
APRIL Molekülhintergrund
APRIL(a proliferation-inducing ligand) is also known as Tumor necrosis factor ligand superfamily member 13, TALL-2, TRDL-1, CD256, TNFSF13, cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. APRIL is a cytokine of the tumor necrosis factor family associated mainly with hematologic malignancies. The closely related TNF family ligands B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serve in the generation and maintenance of mature B-lymphocytes. Both BAFF and APRIL assemble as homotrimers that bind and activate several receptors that they partially share. BAFF-APRIL heteromers of different stoichiometries have distinct receptor-binding properties and activities. In addition, expression of APRIL was regulated by miR-145 in GC cells.
APRIL Molekülalias
APRIL,TNFSF13,TALL-2,TRDL-1,CD256,TALL2,ZTNF2
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Atacicept | TACI-Ig | Phase 3 Clinical | Zymogenetics Inc | Glomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic | Details |
| Zigakibart | BION-1301; FUB523; FUB-523 | Phase 3 Clinical | Aduro Biotech Inc | Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma | Details |
| Povetacicept | ALPN-303; ALPN 30x | Phase 3 Clinical | Alpine Immune Sciences Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis | Details |
| Sibeprenlimab | VIS-649 | Phase 3 Clinical | Visterra Inc | Glomerulonephritis, IGA; Glomerulonephritis | Details |
| IM-21 | IM21; IM-21 | Phase 1 Clinical | Beijing Yimiao Medical Technology Co Ltd | Multiple Myeloma | Details |
| dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology) | Phase 1 Clinical | Wuhan Si'an Medical Technology Co Ltd | Multiple Myeloma | Details | |
| dual anti-BCMA/anti-CD38 CAR T-cell therapy (Shengyan Pharmaceutical Technology/Tongji Medical College) | Phase 1 Clinical | Tongji Medical College | Multiple Myeloma | Details | |
| BCMA-CS1 cCAR T-cell therapy | Phase 1 Clinical | iCell Gene Therapeutics LLC | Multiple Myeloma | Details | |
| anti-BCMA CAR T-cell therapy (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Multiple Myeloma | Details | |
| anti-BCMA CAR T-cell therapy (Kite) | FHVH33-CD8BBZ | Phase 1 Clinical | Teneobio Inc | Multiple Myeloma | Details |
| anti-BCMA CAR T-cell therapy (Yake Biotechnology/Zhejiang University) | Phase 1 Clinical | Shanghai Yake Biotechnology Co Ltd | Multiple Myeloma | Details | |
| CBG-002 | CBG-002 | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Multiple Myeloma | Details |
| BCMA-CD19 cCAR | Phase 1 Clinical | iCell Gene Therapeutics LLC | Lupus Nephritis; Multiple Myeloma; Rejection of organ transplantation; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia | Details | |
| Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
| anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital） | Phase 1 Clinical | Massachusetts General Hospital | Multiple Myeloma | Details | |
| AUR-200 | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| RO-7297089 | RO-7297089; AFM-26; RG-6296 | Phase 1 Clinical | Genentech Inc | Multiple Myeloma | Details |
| APRIL CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| anti-BCMA CAR T-cell therapy engineered to express anti-IL6 scFv and IL1RA (Celledit) | Clinical | Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | ||
| anti-BCMA CAR T-cell therapy (Shanghai GeneChem) | Clinical | Shanghai Genechem Co Ltd | Multiple Myeloma | Details | |
| anti-BCMA/NKG2DL/FAP TCR T-cell therapy (Guangdong VitaLife) | Clinical | Multiple Myeloma | Details | ||
| bispecific anti-CD19/anti-BCMA CAR T-cell therapy (Shanghai Hrain Biotechnology) | HRAIN-002 | Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| BCMA-UCART | BCMA-UCART | Clinical | BRL Medicine Inc | Multiple Myeloma | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Telitacicept | RCT-18; RC-18; RCT18; RC18 | Approved | RemeGen Co Ltd | 泰爱 | Mainland China | Lupus Erythematosus, Systemic | RemeGen Co Ltd | 2021-03-09 | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Nephrosis; Immunoglobulin G4-Related Disease; Sjogren's Syndrome; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic | Details |
Produktrezensionen
W***A2025-10-07
0Menschen mögenProfessional technical support: For this product, they can provide detailed SPR raw data, mass spectrometry analysis reports, etc. High data transparency.
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Produktrezensionen
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main